Straits Times Index
3,097.39 +7.08 (+0.23%) Nikkei
33,231.27 -200.24 (-0.60%) Hang Seng
16,649.36 -180.94 (-1.08%) FTSE 100
7,529.35 +75.60 (+1.01%) Bitcoin USD
41,499.88 +2,073.03 (+5.26%) CMC Crypto 200
858.41 +66.85 (+8.45%)
Iovance Biotherapeutics, Inc. (IOVA)
After hours:
| Previous close | 6.07 |
| Open | 6.05 |
| Bid | 0.00 x 2900 |
| Ask | 0.00 x 3200 |
| Day's range | 5.76 - 6.28 |
| 52-week range | 3.21 - 9.36 |
| Volume | |
| Avg. volume | 7,287,349 |
| Market cap | 1.602B |
| Beta (5Y monthly) | 0.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.08 |
| Earnings date | 26 Feb 2024 - 01 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 20.42 |
Motley FoolWhy Iovance Biotherapeutics Stock Is Jumping Today
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were jumping 10.9% higher as of 11:49 a.m. ET on Monday. The nice gain came after Goldman Sachs initiated coverage on Iovance stock with a buy recommendation. Investors no doubt liked Goldman Sachs' 12-month price target of $12 for Iovance.
GlobeNewswireIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on November 16, 2023 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 59,950 shares of Iovance’s common stock to nine new non-executive employees. The awards
Insider MonkeyIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2023 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2023 Earnings Call Transcript November 7, 2023 Iovance Biotherapeutics, Inc. reports earnings inline with expectations. Reported EPS is $-0.46 EPS, expectations were $-0.46. Operator: Welcome to the Iovance Biotherapeutics Third Quarter and Year-to-Date 2023 Financial Results and Corporate Update Conference Call. My name is Abigail, and I will be your […]
